Results 51 to 60 of about 877,566 (357)

Novel anti-tumour necrosis factor receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in experimental acute lung injury. [PDF]

, 2018
BACKGROUND: Tumour necrosis factor alpha (TNF-α) is a pleiotropic cytokine with both injurious and protective functions, which are thought to diverge at the level of its two cell surface receptors, TNFR1 and TNFR2.

core   +2 more sources

Screening for lung cancer: A systematic review of overdiagnosis and its implications

Molecular Oncology, EarlyView.
Low‐dose computed tomography (CT) screening for lung cancer may increase overdiagnosis compared to no screening, though the risk is likely low versus chest X‐ray. Our review of 8 trials (84 660 participants) shows added costs. Further research with strict adherence to modern nodule management strategies may help determine the extent to which ...
Fiorella Karina Fernández‐Sáenz, Laura de la Torre‐Perez, David R Baldwin, Carlijn van der Aalst, Mangesh Thorat, David Ritchie, Andre L Carvalho, Carolina Espina, Ivan Solà, Carlos Canelo‐Aybar, Moira Magdalena Pissinis, Pablo Alonso‐Coello, Ana Carolina Pereira Nunes Pinto   +12 more
wiley   +1 more source

A nomogram model based on clinical and 3D-EIT parameters for CTEPH diagnosis

Respiratory Research
Background Chronic thromboembolic pulmonary hypertension (CTEPH) is easily misdiagnosed. Three-dimensional (3D) electrical impedance tomography (EIT) can monitor the whole-lung perfusion at the bedside.
Jian Xu, Yuhan Wang, Ying Gong, Lu Wang, Yuanlin Song, Xu Wu   +5 more
doaj   +1 more source

Funding Era Free Speech Theory: Applying Traditional Speech Protection to the Regulation of Anonymous Cyberspace [PDF]

, 2014
Background Blunt trauma is the most frequent mechanism of injury in multiple trauma, commonly resulting from road traffic collisions or falls. Two of the most frequent injuries in patients with multiple trauma are chest trauma and extremity fracture ...
Andreas Seekamp, Claudia Neunaber, Deike Varoga, Frank Hildebrand, Hagen Andruszkow, Matthias Weuster, Mersedeh Tohidnezhad, Nadine Steubesand, Sebastian Lippross, Stefan Rose-John, Stefanie Fitschen-Oestern, Thomas Pufe, Tim Klueter   +12 more
core   +2 more sources

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Impact of pre‐existing interstitial lung abnormal shadow on lung injury development and severity in patients of non‐small cell lung cancer treated with osimertinib

Cancer Medicine, 2022
Background First‐generation epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) sometimes causes lung injury, thereby affecting survival.
Ryota Shibaki, Yuichi Ozawa, Susumu Noguchi, Yusuke Murakami, Eri Takase, Yuichiro Azuma, Masaru Maebeya, Takeya Sugimoto, Atsushi Hayata, Takahiro Hayakawa, Shinya Tamaki, Masanori Nakanishi, Shunsuke Teraoka, Hiroaki Akamatsu   +13 more
doaj   +1 more source

Allosteric modulation of beta1 integrin function induces lung repair in animal model of emphysema. [PDF]

, 2007
Emphysema is a progressive lung disease characterised by loss of lung parenchyma with associated functional changes including decreased tissue elastance. Here we report beta1 integrin is a novel target for tissue repair and regeneration in emphysema.
Chris J. Armit, David J. Harrison, Linda Wilson, Mark Marsden, Rehab J. Al-Jamal, Steven D. Shapiro, Susan McIntyre   +6 more
core   +1 more source

Next‐generation proteomics improves lung cancer risk prediction

Molecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner   +4 more
wiley   +1 more source

An observational study of Donor Ex Vivo Lung Perfusion in UK lung transplantation: DEVELOP-UK [PDF]

, 2016
Background: Many patients awaiting lung transplantation die before a donor organ becomes available. Ex vivo lung perfusion (EVLP) allows initially unusable donor lungs to be assessed and reconditioned for clinical use.
Andreasson, Andreasson, Anyanwu, Arcasoy, Avlonitis, Avlonitis, Behrendt, Benden, Bjørk, Boffini, Boffini, Botha, Brazier, Briggs, Brown, Bury, Charmaz, Christie, Couraud, Curtis, Cypel, Cypel, Cypel, Cypel, Cypel, Cypel, De Perrot, Department of Health, Entwistle, Fielding, Fischer, Fisher, Fisher, Fisher, Fisher, Fisher, Fisher, Gibbs, Glaser, Great Britain, Haugh, Henriksen, Information Services Division, Ingemansson, International Society for Heart and Lung Transplantation, ISD Scotland, Itano, Jirsch, Joint Formulary Committee, Kaba, Kaneda, Kierans, Korovesi, Krutsinger, Lee, Littlefield, Long, Lowton, Lowton, Machuca, Martins, Mays, Moran, Naef, National Health Service, National Heart Lung and Blood Institute, National Institute for Health and Care Excellence, National Institute for Health Care Excellence, NHS Blood and Transplant, NHS Blood and Transplant, NHS Business Service Authority, Office for National Statistics, Okada, OPTUM, Orens, O’Grady, RAND Health, RAND Health Corporation, Renshaw, Roberts, Royal College of Surgeons, Sage, Sanchez, Sanchez, Schaeffer, Siebert, Steen, Steen, Taylor, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Tikkanen, TransMedics, TransMedics, UK Government Department of Constitutional Affairs, van Enckevort, Wallinder, Ware, Warnecke, Warnecke, Wierup, World Medical Organization, XVIVO Perfusion, Zych   +102 more
core   +4 more sources

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source